Related Experiment Video
Updated: Jan 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid Profile and Management of Dyslipidemias in Pregnancy
Constantine E Kosmas1, Loukianos S Rallidis1, Ioannis Hoursalas2
12nd Department of Cardiology, National & Kapodistrian University of Athens, 12462 Athens, Greece.
Insights
Managing dyslipidemia during pregnancy is crucial for preventing atherosclerotic cardiovascular disease (ASCVD) and pregnancy complications. This review covers lipid metabolism changes and management strategies, including lifestyle and pharmacological options.
Area of Science:
- Obstetrics and Gynecology
- Cardiology
- Endocrinology
Background:
- Dyslipidemia significantly elevates the risk of atherosclerotic cardiovascular disease (ASCVD).
- Abnormal maternal lipid profiles during pregnancy are linked to complications like preeclampsia, gestational diabetes, and preterm delivery.
- Elevated ASCVD risk affects both mother and child.
Purpose of the Study:
- To review physiological changes in lipid metabolism during pregnancy.
- To provide an overview of current dyslipidemia management strategies in pregnant women.
- To focus on pharmacological therapy considerations for lipid disorders in pregnancy.
Main Methods:
- Literature review of physiological changes in lipid metabolism during pregnancy.
- Synthesis of current clinical guidelines and research on dyslipidemia management in pregnancy.
- Analysis of safety and efficacy data for pharmacological interventions in pregnant populations.
Main Results:
- Pregnancy involves significant, dynamic alterations in lipid metabolism.
- Management requires individualized approaches combining lifestyle modifications and, when necessary, pharmacotherapy.
- Specific pharmacological agents require careful consideration regarding safety and efficacy in pregnancy.
Conclusions:
- Effective dyslipidemia management is essential for preventing ASCVD and optimizing pregnancy outcomes.
- A multidisciplinary approach integrating lifestyle and targeted pharmacological therapy is key.
- Further research is needed to refine pharmacological strategies for lipid management during pregnancy.
Abstract:
Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD). Abnormal maternal lipid profiles in pregnancy are associated with pregnancy complications including preeclampsia, gestational diabetes, and pre-term delivery as well as increased ASCVD risk for both mother and child. Dyslipidemia management remains a central tenet for atherosclerotic cardiovascular disease prevention for women who are thinking about becoming pregnant or are already pregnant. Effective individualized guidance and multidisciplinary lifestyle/dietary strategies, along with targeted pharmacological interventions, are required for the successful management of lipid disorders in pregnancy in order to optimize outcomes. This review discusses the physiological changes occurring in lipid metabolism during pregnancy and provides an overview of the current strategies for managing dyslipidemia during pregnancy, with a special focus on consideration of pharmacological therapy.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

